Olsitri (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

• Olsitri, a combination antihypertensive, is indicated for conditions related to elevated blood pressure.
• Essential hypertension: lowers systolic and diastolic pressure in patients with primary hypertension.
• Isolated systolic hypertension: reduces high systolic readings in older adults.
• Hypertension requiring triple therapy: provides three complementary mechanisms for patients not controlled on single or dual agents.

• Olmesartan medoxomil blocks angiotensin II AT1 receptors, reducing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth muscle, producing arterial vasodilation. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, increasing diuresis and decreasing plasma volume. Together, the three agents produce additive blood‑pressure‑lowering effects through vascular relaxation, reduced fluid retention, and inhibition of the renin‑angiotensin system.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Peripheral edema, especially of the ankles
• Flushing or warmth sensation
• Fatigue or mild weakness
• Increased urinary frequency

Serious or Rare Side Effects

• Severe hypotension or syncope
• Electrolyte disturbances such as hyperkalemia, hyponatremia, or hypokalemia
• Acute kidney injury or worsening renal function
• Angioedema or severe allergic reactions
• Liver enzyme elevation or hepatitis
• Blood dyscrasias such as leukopenia or thrombocytopenia

Before initiating Olsitri, clinicians should consider several safety aspects.

• Blood pressure monitoring: ensure adequate control and avoid excessive drops.
• Renal function assessment: check serum creatinine and eGFR, especially in patients with pre‑existing kidney disease.
• Electrolyte surveillance: monitor potassium and sodium levels due to the thiazide component.
• Hepatic impairment: use with caution in patients with liver disease as metabolism may be altered.
• Hypersensitivity: discontinue if signs of rash, angioedema, or anaphylaxis appear.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Olsitri may interact with several medicines that affect blood pressure, electrolytes, or drug metabolism.

Major Interactions (Avoid)

• Concomitant use with aliskiren in diabetic patients: risk of renal impairment and hyperkalemia.
• Dual renin‑angiotensin system blockade (ACE inhibitor or another ARB): may cause severe hypotension and kidney injury.
• Potassium‑sparing diuretics (e.g., spironolactone): increase risk of hyperkalemia.
• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): raise amlodipine plasma levels.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives (beta‑blockers, ACE inhibitors): additive blood‑pressure lowering.
• Lithium: thiazide component can raise lithium concentrations.
• Digoxin: possible increase in serum digoxin levels.
• Additional thiazide diuretics: heightened electrolyte disturbances.
• Alcohol: may enhance hypotensive effect.